NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NexGel, Inc. has announced the pricing of its initial public offering (IPO) of 2,585,000 shares at $5.50 per share, generating gross proceeds of approximately $14.2 million. Each share is offered with a warrant for the same amount. The IPO is set to begin trading on Nasdaq under the symbols 'NXGL' and 'NXGLW' on December 22, 2021, with a closing date expected on December 27, 2021. Proceeds will be used for corporate purposes, including product development and potential acquisitions.